AT247, a promising candidate in the pursuit for next generation insulins to improve glycemic control Cambridge, UK, 16 December 2020: Arecor Limited ( Arecor or the Company ), the biopharmaceutical company advancing today s therapies to enable healthier lives, today announces that Diabetes Care has published data for the Phase I clinical trial of AT247, its ultra-rapid acting insulin product candidate. The manuscript titled Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double blind, Crossover Study in Men with Type 1 Diabetes is available online from today via https://care.diabetesjournals.org/lookup/doi/10.2337/dc20-1017. In the Phase I clinical study, AT247 exhibited an earlier insulin appearance, exposure, and offset, with corresponding enhanced early glucose-lowering effect compared with both NovoRapid